 | |
| Clinical data | |
|---|---|
| Trade names | Carafate |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a681049 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, rectal |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 3-5% (local acting) |
| Metabolism | GI; liver: unknown |
| Elimination half-life | unknown |
| Excretion | Feces, urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C12H54Al16O75S8 |
| Molar mass | 2086.67 g·mol−1 |
  (what is this?) (verify) | |
Sucralfate, sold under various brand names, is a medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.[3][4][5] Its usefulness in people infected by H. pylori is limited.[3] It is used by mouth and rectally.[3][5]
Common side effects include constipation.[3] Serious side effects may include bezoar formation and encephalopathy.[6] Use appears to be safe in pregnancy and breastfeeding.[6] How it works is unclear but is believed to involve binding to the ulcer and protecting it from further damage.[3][6]
Sucralfate was approved for medical use in the United States in 1981.[3] It is available as a generic medication.[6] In the United States the wholesale cost is about US$0.22 per dose.[7] In 2017, it was the 218th most commonly prescribed medication in the United States, with more than two million prescriptions.[8][9]
References
edit- ^ Merck Index, 12th Edition, 9049.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020.
- ^ a b c d e f "Sucralfate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists.
- ^ Maton PN (November 2003). "Profile and assessment of GERD pharmacotherapy". Cleveland Clinic Journal of Medicine. 70 Suppl 5: S51-70. doi:10.3949/ccjm.70.Suppl_5.S51. PMID 14705381.
- ^ a b Mendenhall WM, McKibben BT, Hoppe BS, Nichols RC, Henderson RH, Mendenhall NP (October 2014). "Management of radiation proctitis". American Journal of Clinical Oncology. 37 (5): 517–23. doi:10.1097/COC.0b013e318271b1aa. PMID 23241500. S2CID 12129192.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 73. ISBN 9780857113382.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Sucralfate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.